About Seragon Pharmaceuticals
Seragon Pharmaceuticals is a company based in San Diego (United States) founded in 2013 was acquired by Genentech in July 2014. Seragon Pharmaceuticals has raised $30 million across 1 funding round from investors including Genentech, Orbimed and The Column Group. Seragon Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Seragon Pharmaceuticals
Seragon Pharmaceuticals has successfully raised a total of $30M through 1 strategic funding round. The most recent funding activity was a Series A round of $30 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Seragon Pharmaceuticals
Seragon Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Genentech, Orbimed and The Column Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Locked | Locked | Locked | |
|
Biotech sectors are targeted for investments by Topspin Fund.
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked |
Investor details for Seragon Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Seragon Pharmaceuticals
Investment portfolio details for Seragon Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Seragon Pharmaceuticals
Detailed financials for Seragon Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Seragon Pharmaceuticals Comparisons
Peer comparison for Seragon Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Seragon Pharmaceuticals
Seragon Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Seragon Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Seragon Pharmaceuticals
Complete news archive for Seragon Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seragon Pharmaceuticals
Seragon Pharmaceuticals was founded in 2013.
Seragon Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Seragon Pharmaceuticals is a funded company, having raised a total of $30M across 1 funding round to date.
Seragon Pharmaceuticals was founded in 2013 and is based in San Diego, United States. Operations focus on the biotechnology sector, specifically the development of orally active selective estrogen receptor degraders (SERDs) for estrogen receptor-dependent breast cancer. These compounds function as antagonists that induce receptor degradation, with multiple candidates identified for their pharmacokinetic profiles supporting anti-tumor activity.
Seragon Pharmaceuticals's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Seragon Pharmaceuticals has 6 investors. Key investors include Genentech, Orbimed, The Column Group, venBio, and Topspin Fund.